KẾT QUẢ ĐIỀU TRỊ VÀ TÁC DỤNG KHÔNG MONG MUỐN HÓA TRỊ TÂN BỔ TRỢ PHÁC ĐỒ PACLITAXEL – CARBOPLATIN TRONG UNG THƯ BIỂU MÔ BUỒNG TRỨNG GIAI ĐOẠN III, IV TẠI BỆNH VIỆN TỈNH PHÚ THỌ

Abstract

Objective: To evaluate the treatment response and adverse effects of neoadjuvant chemotherapy with the Paclitaxel–Carboplatin regimen in patients with stage IIIC and IV epithelial ovarian cancer (EOC) at Phu Tho Provincial General Hospital. Subjects and Methods: A combined retrospective and prospective descriptive study was conducted on 58 patients with stage IIIC and IV EOC who received neoadjuvant chemotherapy with the Paclitaxel–Carboplatin regimen at Phu Tho Provincial General Hospital from January 2019 to March 2025. Results: The overall response rate according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) was 93.1%. Patients' performance status improved significantly, with the proportion of those with an ECOG score of 2 decreasing from 36.2% before treatment to 5.2% after neoadjuvant chemotherapy. The mean serum CA-125 level prior to treatment was 1500.18 ± 1549.1 U/mL, which significantly decreased to 269.59 ± 742 U/mL after three cycles of chemotherapy. This difference was statistically significant (p < 0.005  p = 0.000). The rate of optimal cytoreductive surgery was 93.1%. The most common adverse event was leukopenia (22.4%), with grade 3–4 leukopenia observed in only 6.9% of patients. Other adverse events, including anemia, nausea, diarrhea, and peripheral neuropathy, were infrequent and limited to grade 1–2. Conclusion: Neoadjuvant chemotherapy with the Paclitaxel–Carboplatin regimen in stage IIIC–IV epithelial ovarian carcinoma patients yields a high therapeutic response rate, increases the likelihood of optimal cytoreduction, and is generally associated with mild adverse effects (grade I–II).